<DOC>
<DOCNO>EP-0614906</DOCNO> 
<TEXT>
<INVENTION-TITLE>
Mononucleotide analogues and intermediates therefor.
</INVENTION-TITLE>
<CLASSIFICATIONS>C07F900	C07F930	C07H900	C07H904	C07H1300	C07H1306	C07H1900	C07H1906	C07H1910	C07H1916	C07H1920	C07H2100	C07H2100	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>C07F	C07F	C07H	C07H	C07H	C07H	C07H	C07H	C07H	C07H	C07H	C07H	C07H	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>C07F9	C07F9	C07H9	C07H9	C07H13	C07H13	C07H19	C07H19	C07H19	C07H19	C07H19	C07H21	C07H21	</CLASSIFICATIONS-FOURTH>
<ABSTRACT>
A compound of formula 

where
 

R¹ is hydrogen or a protecting group Q;
 

R² is hydrogen, a C₁-C₈ aliphatic radical, a C₆-C₁₅ aromatic radical, a C₃-C₈ 
cycloaliphatic radical, a C₇-C₁₃ araliphatic radical, an alkali metal ion or an 

ammonium ion;
 

R³ and R⁴ are independently hydrogen, halogen or hydroxy;
 

R⁵ is C₆-C₁₀ aryloxythiocarbonyloxy, the C₆-C₁₀ aryl group being unsubstituted 
or substituted, or R⁵
a
;
 

R⁵
a
 is hydrogen, fluorine, chlorine, hydroxy, -OR⁸, -OCOR⁸ or silyloxy 
substituted by three C₁-C₁₅ hydrocarbyl groups;

 
R⁶ is hydrogen, a C₁-C₁₀ aliphatic radical, a C₆-C₁₅ aromatic radical, a C₇-C₁₆ 

araliphatic radical, -COR⁹, -SO₂R⁹ or silyl substituted by three C₁-C₁₅ 
hydrocarbyl groups;

 
R⁷ is a monovalent nucleoside base radical, hydroxyl, -OR⁸ or -OCOR⁸, and and

 
R⁹ are independently a C₁-C₁₀ aliphatic radical, a C₃-C₈ cycloaliphatic radical, a 

C₆-C₁₅ aromatic radical or a C₇-C₁₆ araliphatic radical; or
 

R⁵ and the indicated R⁶O-together denote an isopropylidenedioxy group or R⁵ 
and R⁷ together denote an isopropylidenedioxy group, provided that when R⁵ and 

R⁷ together denote isopropylidenedioxy, R¹ R², R³ R⁴ and R⁶ are not all 
hydrogen. 
</ABSTRACT>
<APPLICANTS>
<APPLICANT-NAME>
CIBA GEIGY AG
</APPLICANT-NAME>
<APPLICANT-NAME>
CIBA-GEIGY AG
</APPLICANT-NAME>
</APPLICANTS>
<INVENTORS>
<INVENTOR-NAME>
BAXTER ANTHONY DAVID
</INVENTOR-NAME>
<INVENTOR-NAME>
BAYLIS ERIC KEITH
</INVENTOR-NAME>
<INVENTOR-NAME>
COLLINGWOOD STEPHEN PAUL
</INVENTOR-NAME>
<INVENTOR-NAME>
DE MESMAEKER ALAIN
</INVENTOR-NAME>
<INVENTOR-NAME>
SCHMIT CHANTAL
</INVENTOR-NAME>
<INVENTOR-NAME>
TAYLOR ROGER JOHN
</INVENTOR-NAME>
<INVENTOR-NAME>
BAXTER, ANTHONY DAVID
</INVENTOR-NAME>
<INVENTOR-NAME>
BAYLIS, ERIC KEITH
</INVENTOR-NAME>
<INVENTOR-NAME>
COLLINGWOOD, STEPHEN PAUL
</INVENTOR-NAME>
<INVENTOR-NAME>
DE MESMAEKER, ALAIN
</INVENTOR-NAME>
<INVENTOR-NAME>
SCHMIT, CHANTAL
</INVENTOR-NAME>
<INVENTOR-NAME>
TAYLOR, ROGER JOHN
</INVENTOR-NAME>
</INVENTORS>
<DESCRIPTION>
This invention relates to mononucleotide analogues which are useful as intermediates in 
the synthesis of oligonucleotide analogues for use as anti-sense probes for inhibiting gene 
expression in biological systems. It also relates to intermediates for the mononucleotide 
analogues. The compounds of the invention may themselves be useful as pharmaceuticals in the 
treatment of viruses such as influenza, herpes and HIV and in the treatment of diseases 
which are mediated through inhibition or activation of enzymes/receptors which recognise 
nucleotide 5¹ monophosphates as substrates or ligands. Accordingly, the present invention provides a compound of formula 
where
 
R¹ is hydrogen or a protecting group Q;
 
R² is hydrogen, a C₁-C₈ aliphatic radical, a C₃-C₈ cycloaliphatic radical, a C₆-C₁₅ 
aromatic radical, a C₇-C₁₃ araliphatic radical, an alkali metal ion or an ammonium ion;
 
R³ and R⁴ are independently hydrogen, halogen or hydroxy;
 
R⁵ is C₆-C₁₀ aryloxythiocarbonyloxy, the C₆-C₁₀ aryl group being unsubstituted or 
substituted, or R⁵a;
 
R⁵a is hydrogen, fluorine, chlorine, hydroxy, -OR⁸, -OCOR⁸ or silyloxy substituted by  
 
three C₁-C₁₅ hydrocarbyl groups;
 
R⁶ is hydrogen, a C₁-C₁₀ aliphatic radical, a C₆-C₁₅ aromatic radical, a C₇-C₁₆ araliphatic 
radical, -COR⁹, -SO₂R⁹ or silyl substituted by three C₁-C₁₅ hydrocarbyl groups;
 
R⁷ is a monovalent nucleoside base radical, hydroxy, -OR⁸ or -OCOR⁸, 
and
 
R⁸ and R⁹ are independently a C₁-C₁₀ aliphatic radical, a C₃-C₈ cycloaliphatic radical, a 
C₆-C₁₅ aromatic radical or a C₇-C₁₆ araliphatic radical; or
 
R⁵ and the indicated R⁶O together denote an isopropylidenedioxy group or R⁵ and R⁷ 
together denote an isopropylidenedioxy group, provided that when R⁵ and R⁷ together 
denote an isopropylidenedioxy group, R¹, R²,R³,R⁴, and R⁶ are not all hydrogen. Generally, in compounds of formula I,
 
R² is hydrogen, substituted or unsubstituted C₁-C₈ alkyl, C₃-C₈ cycloalkyl, C₆-C₁₅ aryl or 
C₇-C₁₃ aralkyl, an alkali metal ion or an ammonium ion;
 
R⁵ as R⁵a is hydrogen, fluorine, chlorine, hydroxy, C₁-C₁₀ alkoxy, C₂-C₁₀ alkenoxy, 
C₆-C₁₅ aryloxy, C₇-C₁₆ aralkyloxy, -OCOR⁸ or silyloxy substituted by three C₁-C₁₅ 
hydrocarbyl groups;
 
R⁶ is hydrogen, substituted or unsubstituted C₁-C₁₀ alkyl, C₂-C₁₀ alkenyl, C₆-C₁₅ aryl or 
C₇-C₁₆ aralkyl, -COR⁹, -SO₂R⁹ or silyl substituted by three C₁-C₁₅ hydrocarbyl groups; 
and
 
R⁸ and R⁹ are independently substituted or unsubstituted C₁-C₁₀ alkyl, C₂-C₁₀ alkenyl, 
C₃-C₈ cycloalkyl, C₆-C₁₅ aryl or C₇-C₁₆ aralkyl. The
</DESCRIPTION>
<CLAIMS>
A compound of formula 
 

where 
R¹ is hydrogen or a protecting group Q; 

R² is hydrogen, a C₁-C₈ aliphatic radical, a C₆-C₁₅ aromatic radical, a C₃-C₈ 
cycloaliphatic radical, a C₇-C₁₃ araliphatic radical, an alkali metal ion or an 

ammonium ion; 
R³ and R⁴ are independently hydrogen, halogen or hydroxy; 

R⁵ is C₆-C₁₀ aryloxythiocarbonyloxy, the C₆-C₁₀ aryl group being unsubstituted 
or substituted, or R⁵a; 

R⁵a is hydrogen, fluorine, chlorine, hydroxy, -OR⁸, -OCOR⁸ or silyloxy 
substituted by three C₁-C₁₅ hydrocarbyl groups;. 

R⁶ is hydrogen, a C₁-C₁₀ aliphatic radical, a C₆-C₁₅ aromatic radical, a C₇-C₁₆ 
araliphatic radical, -COR⁹, -SO₂R⁹ or silyl substituted by three C₁-C₁₅ 

hydrocarbyl groups; 
R⁷ is a monovalent nucleoside base radical, hydroxyl, -OR⁸ or -OCOR⁸, and 

R⁸ and R⁹ are independently a C₁-C₁₀ aliphatic radical, a C₃-C₈ cycloaliphatic 
radical, a C₆-C₁₅ aromatic radical or a C₇-C₁₆ araliphatic radical; or 

R⁵ and the indicated R⁶O-together denote an isopropylidenedioxy group or R⁵ 
 

and R⁷ together denote an isopropylidenedioxy group, 
provided that when R⁵ and R⁷ together denote an isopropylidenedioxy group, R¹, 

R², R³, R⁴ and R⁶ are not all hydrogen. 
A compound according to claim 1, in which R² is hydrogen, substituted or 
unsubstituted C₁-C₈ alkyl, C₃-C₈ cycloalkyl, C₆-C₁₅ aryl or C₇-C₁₃ aralkyl, an 

alkali metal ion or an ammonium ion; 
R⁵ as R⁵a is hydrogen, fluorine, chlorine, hydroxy, C₁-C₁₀ alkoxy, C₂-C₁₀ 

alkenoxy, C₆-C₁₅ aryloxy, C₇-C₁₆ aralkyloxy, -OCOR⁸ or silyloxy substituted by 
three C₁-C₁₅ hydrocarbyl groups; 

R⁶ is hydrogen, substituted or unsubstituted C₁-C₁₀ alkyl, C₂-C₁₀ alkenyl, C₆-C₁₅ 
aryl or C₇-C₁₆ aralkyl, -COR⁹, -SO₂R⁹ or silyl substituted by three C₁-C₁₅ 

hydrocarbyl groups; and 
R⁸ and R⁹ are independently substituted or unsubstituted C₁-C₁₀ alkyl, C₂-C₁₀ 

alkenyl, C₃-C₈ cycloalkyl, C₆-C₁₅ aryl or C₇-C₁₆ aralkyl. 
A compound according to claim 1, which is a stereoisomer of formula 
 

where R¹ to R⁷ are as defined in claim 1. 
A compound according to any of the preceding claims, in which the protecting 
group Q is of formula  

where R¹⁰ is hydrogen, C₁-C₁₀ alkyl, C₃-C₈ cycloalkyl, C₆-C₁₀ aryl or C₇-C₁₁ 
aralkyl and R¹¹ and R¹² are independently C₁-C₁₀ alkyl; or the protecting group 

Q is of formula 
 

where R¹³ and R¹⁴ are independently C₁-C₁₀ alkyl or R¹³ is C₁-C₁₀ alkyl and R¹⁴ 
is C₆-C₁₀ aryl. 
A compound according to claim 4, in which R¹⁰ is hydrogen or C₁-C₄ alkyl, R¹¹ 
and R¹² are each C₁-C₄ alkyl and R¹³ and R¹⁴ are each C₁-C₄ alkyl. 
A compound according to any of the preceding claims, in which R² is hydrogen, 
unsubstituted or substituted C₁-C₆ alkyl or an unsubstitued or substituted 

ammonium ion. 
A compound according to any of the preceding claims, in which R³ and R⁴ are 
each hydrogen. 
A compound according to any of claims 1 to 7, in which R⁵ is hydrogen, hydroxy, 
C₁-C₄ alkoxy, -OCOR⁸ where R⁸ is C₁-C₁₀ alkyl, or C₁-C₄ alkyl- or halogen-substituted 

phenyloxythiocarbonyloxy, or R⁵ together with R⁷ denotes an 
isopropylidenedioxy group or R⁵ together with R⁶O- denotes an 

isopropylidenedioxy group; R⁶ is hydrogen, C₇-C₉ aralkyl, -COR⁹ or -SO₂R⁹ 
where R⁹ is unsubstituted or substituted C₁-C₄ alkyl or C₆-C₁₀ aryl, C₁-C₆ alkyldi 

(C₆-C₈ aryl) silyl or R⁶ together with the attached oxygen atom and R⁵ denotes an 
 

isopropylidenedioxy group; and R⁷ is hydroxy, -COR⁸ where R⁸ is C₁-C₁₀ alkyl 
or an unsubstituted or substituted thyminyl, cytosinyl, guaninyl or adeninyl 

group, or R⁷ together with R⁵ denotes an isopropylidenedioxy group. 
A compound according to any of claims 1 to 3, in which 
R¹ is hydrogen or a protecting group Q of formula II as defined in claim 4, in 

which R¹⁰ is hydrogen, or methyl and R¹¹ and R¹² are each ethyl; R² is hydrogen, 
methyl or ethyl; R³, R⁴ and R⁵ are each hydrogen; R⁶ is hydrogen, -COR⁹ where 

R⁹ is phenyl, 4-nitrophenyl or alpha-naphthyl, -SO₂R⁹ where R⁹ is methyl or 
p-tolyl, or tert-butyldiphenylsilyl; and R⁷ is thyminyl or 

N-(4-nitrobenzoyl)thyminyl; or R⁵ and R⁷ together denote an 
isopropylidenedioxy group; or 

R¹ is hydrogen or a protecting group of formula III as defined in claim 4, in 
which R¹³ and R¹⁴ are each methyl; R² is hydrogen, methyl, ethyl, isobutyl, 

ammonium or triethylammonium; R³ and R⁴ are each hydrogen; R⁵ is hydrogen, 
hydroxy, methoxy,-OCOCH₃or p-tolyloxythiocarbonyloxy, R⁶ is hydrogen, 

benzyl or -COR⁹ where R⁹ is methyl or 4-nitrophenyl; and R⁷ is hydroxy, 
-OCOCH₃, thyminyl, N-benzyloxymethylthyminyl, cytosinyl,N-acetylcytosinyl, 

N-benzoylcytosinyl, guaninyl, adeninyl or N-benzoyladeninyl; or R⁵ and R⁷ 
together denote an isopropylidenedioxy group, or R⁵ together with R⁶O- denotes 

an isopropylidenedioxy group. 
A process for the preparation of a compound according to claim 1, in which R¹ is 
a protecting group Q and R² is Ra² which is unsubstituted or substituted C₁-C₈ 

alkyl, C₃-C₈ cycloalkyl or C₇-C₁₃ aralkyl, which comprises reacting an oxetane 
of formula 

 
where B is a monovalent nucleoside base radical and R⁵a is as defined in claim 1, 

with an organometallic compound of formula  
where R³ and R⁴ are as defined in claim 1, Qa is a group Q of formula II as 

defined in claim 4, and M is lithium or magnesium, in the presence of a Lewis 
acid and, optionally, where a compound where R⁶ is other t
han hydrogen is 
required, reacting the resulting product with either a compound of formula 

Ra⁶X   VI 
or a compound of formula 

 
where Ra⁶ is the same as R⁶ as defined in claim 1 except that Ra⁶ cannot be 

hydrogen, R⁹ is as defined in claim 1 and X is a halogen atom or a hydroxyl 
group. 
A process for the preparation of a compound according to claim 1, in which R¹ is 
a protecting group Q, R² is Ra² as defined in claim 10, R³ and R⁴ are each 

hydrogen and R⁵ and R⁷ together denote an isopropylidenedioxy group, which 
comprises reacting an olefinic acetonide of formula 

 
where R⁶ is as defined in claim 1, with a phosphinate of formula  

where Q is as defined in claim 1 and Ra² is as defined in claim 10, in the presence 
of a free radical initiator, the reaction product optionally being reacted with a 

hydrolysing agent for acetonide groups, to produce a compound according to 
claim 1 in which R⁵ and R⁷ are each hydroxy. 
A process for the preparation of a compound according to claim 1 in which R¹ is a 
protecting group Q, and R⁵ and R⁷ are each -OCOR⁸, which comprises 

esterifying a compound of formula 
 

where Q and R⁶ are as defined in claim 1 and Ra² is as defined in claim 10, with 
an acid of formula R⁸ COOH or an anhydride or acid halide thereof, where R⁸ is 

as defined in claim 1. 
A process for the preparation of a compound according to claim 1 in which R¹ is a 
protecting group Q, R² is Ra² and R⁷ is a monovalent nucleoside base radical B 

which comprises glycosylation of a compound of formula 
 

where Q, R⁶ and R⁸ are as defined in claim 1, and Ra² is as defined in claim 10, 
 

with a base of formula 
BH   XXIII 

where B is a monovalent nucleoside base radical. 
A process for the preparation of a compound according to claim 1 in which R¹ is a 
protecting group Q, R⁵ is hydroxy, R⁶ is hydrogen and R⁷ is a monovalent 

nucleoside base radical which comprises subjecting a compound of formula 
 

where Q, and R⁸ are as defined in claim 1, B is a monovalent nucleoside base 
radical, Ra² is as defined in claim 10 and R⁶ is -COR⁹ or -SO₂R⁹ where R⁹ is as 

defined in claim 1, to mild basic hydrolysis to hydrolyse the -OCOR⁸ group and 
the -OCOR⁹ or -SO₂R⁹ group. 
A process for the preparation of a compound according to claim 1 in which R¹ is a 
protecting group Q, R² is Ra², R³ and R⁴ are each hydrogen and R⁷ is a 

monovalent nucleoside base radical, which comprises reacting an olefinic 
nucleoside of formula 

 
where B is a monovalent nucleoside base radical, and R⁵a and R⁶ are as defined 

in claim 1, with a phosphinate of formula XIV as defined in claim 11 in the 
presence of a free radical initiator. 
A process for the preparation of a compound according to claim 1 in which R¹ is a 
protecting group Q of formula II as defined in claim 4, R² is R²a as defined in 

claim 10, R³ and R⁴ are each hydrogen, R⁶ is hydrogen and R⁵ and R⁷ together 
 

denote an isopropylidenedioxy group, which comprises reacting a compound of 
formula 

 
with an organometallic compound of formula V as defined in claim 10, in the 

presence of a Lewis acid. 
A process for the preparation of a compound according to claim 1 in which R¹ is 
hydrogen, which comprises hydrolysing a compound according to claim 1 where 

R¹ is a protecting group Q and R² is Ra² as defined in claim 10, to replace Q by a 
hydrogen atom and, optionally, to replace Ra² by a hydrogen atom. 
A process according to claim 17, in which Q is a group of formula III as defined 
in claim 4 and hydrolysis is effected under basic conditions. 
Use of a compound according to any of claims 1 to 9 in the synthesis of a 
dinucleotide analogue or an oligonucleotide analogue. 
A pharmaceutical composition comprising as active ingredient a compound 
according to any of claims 1 to 9. 
</CLAIMS>
</TEXT>
</DOC>
